Genentech Moderate Alzheimer’s Disease Study - LAURIET (CLOSED)
What is the Genentech LAURIET study?
This is a voluntary research study to evaluate the effects of an investigational medication on moderate Alzheimer’s disease (AD). This study will include approximately 260 participants from 80 sites in North America and Europe. People who are interested in participating will be screened for moderate cognitive impairment to see if they qualify. This study could last up to 3 years, depending on how long participants choose to remain in the clinical trial. Participants are monitored for safety and cognitive function throughout the trial. Genentech, Inc., a member of the Roche Group, is sponsoring this research study.
What is the purpose of the Genentech LAURIET study?
The purpose of this study is to evaluate the safety and effectiveness of the investigational drug, MTAU9937A, in eligible participants with moderate AD. Participants will be randomly assigned (like flipping a coin) to receive either MTAU9937A or a placebo to compare their effects on AD. A placebo is an inactive substance that looks like MTAU9937A, but has no effect. The investigational drug will be administered intravenously (in your vein) at various time points during the study.
This is a voluntary research study for people ages 50-85 years old. Everyone undergoes the Informed Consent process, during which time people can agree to participate in the study or not. Those who agree to participate in this study will undergo testing and evaluation by the study doctor for moderate AD to see if they qualify for the study. All qualified participants must have a study partner with whom they spend regular time and would be able to support them through the duration of the study.
To learn more about the Genentech moderate Alzheimer’s disease study, please call (401) 455-6402 or send an e-mail to email@example.com. Ask about the “Genentech LAURIET trial.”